<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04486963</url>
  </required_header>
  <id_info>
    <org_study_id>TSL-TCM-SHJSMW-IIa</org_study_id>
    <nct_id>NCT04486963</nct_id>
  </id_info>
  <brief_title>A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Ranibizumab Injected, Multicenter Phase II Clinical Study on the Efficacy and Safety of Sanhuangjingshimingwan in the Wet AMD(Qi and Yin Deficiency, Phlegm-blood Stasis Syndrome )Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tasly Pharmaceutical Group Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tasly Pharmaceutical Group Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to evaluate the efficacy and safety of Sanhuangjingshimingwan in Wet AMD.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is to evaluate the efficacy and safety of Sanhuangjingshimingwan,give two times a
      day versus placebo in wAMD .The clinical phase of the study comprises a 6-months double-blind
      treatment period, resulting in 6.5-months overall duration of the study for each patient.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 16, 2020</start_date>
  <completion_date type="Anticipated">June 10, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The average number of reinjections</measure>
    <time_frame>at week 24</time_frame>
    <description>The subject is injected with Anti-VEGF（Vascular Endothelial Growth Factor） injection once 4 weeks if needed.Compare with the average shoot number of Anti-VEGF injections in both arms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the percentage of subjects in both arms receiving reinjection of Anti-VEGF injection</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>The subject is injected with Anti-VEGF injection once weeks if needed.Compare with the percentage of subjects who reinjected Anti-VEGF injections in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare the average number of days between the second injection and baseline injection</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>The subject is injected with Anti-VEGF injection once 4 weeks if needed.Compare with the average number of days between the second injection and baseline injection in both arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BCVA</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>The subject is tested the vision(BCVA) once 4 weeks with ETDRS visual chart.Compare every visit BCVA with baseline BCVA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare every visit BCVA increasing &gt;5, &gt;10 and &gt; 15 letters with baseline BCVA</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>The proportion of subjects who increased BCVA &gt;5, &gt;10 and &gt; 15 letters at each visit compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare every visit BCVA decreasing＜5, ＜10 and ＜ 15 letters with baseline BCVA</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>The proportion of subjects who decreased BCVA ＜5, ＜10 and ＜15 letters at each visit compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare BCVA decreasing≥15, ≥30 letters with baseline BCVA</measure>
    <time_frame>at week 24</time_frame>
    <description>The proportion of subjects who decreased BCVA ≥15, ≥30 letters at 24 week compared with the baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Central Retinal Thickness (CRT)</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>Change from Baseline in CRT as measured by Optical Coherence Tomography (OCT) over the study duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Choroidal Neovascularization (CNV) area</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>Change from Baseline in CNV area as measured by Optical Coherence Tomography Angiography(OCTA) over the study duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in leakage area</measure>
    <time_frame>at week 24</time_frame>
    <description>Change from Baseline in leakage area as measured by Fluorescein Angiography (FA) at week 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the number of polypoid choroidal vasculopathy(PCV) and Branching vascular network(BVN) area</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>Change from Baseline in the number of PCV and BVN area as measured by Indocyanine Green Angiography(ICGA) over the study duration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in TCM(Traditional Chinese Medicine) syndrome scores</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>Compared wth baseline the scores of changes of TCM syndrome Evaluation at each visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in the effective TCM syndrome scores</measure>
    <time_frame>at screening;at week 4;at week 8;at week 12;at week 16;at week 20;at week 24</time_frame>
    <description>Change from Baseline in the proportion of subjects who decreased TCM syndrome scores.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Age-related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Sanhuangjingshimingwan group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sanhuangjingshimingwan,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sanhuangjingshimingwan Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sanhuangjingshimingwan placebo,12g/bag,1 bag,Bid.Anti VEGF injection will be injected monthly if needed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sanhuangjingshimingwan</intervention_name>
    <description>Sanhuangjingshimingwan,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.</description>
    <arm_group_label>Sanhuangjingshimingwan group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sanhuangjingshimingwan Placebo</intervention_name>
    <description>Sanhuangjingshimingwan Placebo,12g,Bid,6 months.Anti VEGF injection will be injected monthly if needed.</description>
    <arm_group_label>Sanhuangjingshimingwan Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must meet the following criteria for entry into the trail:

               1. Meet the diagnostic criteria for wAMD.

               2. Meet the Traditional Chinese Medicine diagnostic criteria for Qi and Yin
                  Deficiency, Phlegm-blood Stasis Syndrome.

               3. Presence of choroidal neovascularization secondary to wAMD, and/or simple eye
                  with blood, edema, leakage, hard exudation in or below the retina, and detachment
                  of retinal pigment epithelium or neuroepithelium epithelium.

               4. 50 years≤Age≤80 years of either gender.

               5. BCVA 25 - 78 ETDRS letters(0.06~0.6, inclusive).

               6. Signed informed consent form.

        Exclusion Criteria:

          -  Subjects who meet any of the following criteria will be excluded from study entry:

               1. Presence of pathological myopia,high myopia caused of secondary choroidal
                  neovascularization, glaucoma, diabetic retinopathy, retinal arteriovenous
                  obstruction, optic neuropathy (optic neuritis, atrophy, papillary edema), macular
                  hole, acute phase of intraocular inflammation.

               2. Only retinal pigment epithelium-retinal detachment.

               3. The CNV area is more than 12 optic disk area (30mm2).

               4. Subfoveal structural damage or fibrosis.

               5. Subjects that have unclear refractive stroma(e.g.vitreous hemorrhage, cataracts)
                  caused fundus observation difficulty or undergone vitrectomy.

               6. Subjects that have presence of other causes of choroidal neovascularization.

               7. Subjects that have participated in other study of treatment with study drug
                  within the last 3 months before the screening.

               8. Subjects that have treated with photodynamic therapy, external beam radiological
                  therapy, argon laser photocoagulation in macular area, macular surgery,
                  transpupillary thermotherapy, hormone to treat wAMD in any eye within the last 6
                  months before the screening.

               9. Subjects that have undergone previous any eye surgery(except eyelid surgery).

              10. Subjects that have intravitreal anti-VEGF injections in the past 3 months.

              11. Subjects with history of fundus fluorescein and indocyanine green allergy.

              12. Subjects that have any contraindications in the directions of
                  ranibizumab(LUCENTIS)injection.

              13. Subjects that have had severe heart disease in the last 6 months,such as
                  congestive heart failure，unstable angina，acute coronary syndrome，myocardial
                  infarction，Coronary revascularization，artery thrombosis, and ventricular
                  arrhythmia that need treatment.

              14. Subjects with uncontrolled hypertension（After antihypertension treatment
                  SBP≥140mmHg、DBP≥90mmHg）.

              15. PLT≤100×109/L; Coagulation function disorders;TBIL（Total Bilirubin）&gt;1.5×UNL（Upper
                  Limits of Normal）;ALT（Alanine Transaminase）&gt;2.5×UNL or AST（Aspartate
                  aminotransferase）&gt;2.5×UNL;Cr（Creatinine）&gt;1.5×UNL.

              16. Subjects with uncontrolled disease history, such as serious mental, neurological,
                  respiratory, immune, blood and other system diseases, malignant tumors and that
                  not suitable for the study per the investigator's judgment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Liu</last_name>
    <role>Study Director</role>
    <affiliation>Tasly Group, Co. Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Liu</last_name>
    <phone>022-86343626</phone>
    <email>liurui2@tasly.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ning Dai</last_name>
    <phone>022-86343653</phone>
    <email>daining@tasly.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hong Dai</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wenbin Wei</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jingxue Ma</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai General Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xun Xu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Eye Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mei Han</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University Eye Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhiqing Li</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>wAMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

